FindTrial
Sign In

Evaluation of Thoracic Tumors With 18F-FMT and 18F-FDG PET-CT A Clinicopathological Study

Evaluation of Thoracic Tumors With 18F-FMT and 8F-FDG PET-CT: A Clinicopathological Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00698373
Enrollment
Unknown
Registered
2008-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2008-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

Fluorine-18-α-methyltyrosine,, Positron emission tomography,, Fluorine-18-fluorodeoxyglucose,, Lung cancer,

Brief summary

L-\[3-18F\]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The aim of this study was to determine whether PET-CT with 18F-FMT provides additional information for the preoperative diagnostic workup as compared with 18F-FDG PET. Tumor uptake of 18F-FMT was compared with several immunohistochemical markers including L-type amino acid transporter 1 (LAT1).

Interventions

None listed

Sponsors

J~pharma
CollaboratorINDUSTRY
Gunma University
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with indeterminate pulmonary nodule suspicious of lung cancer

Exclusion criteria

* Patients with other malignancies and those who had received cancer treatment within the past 5 years were excluded.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026